- DataHow secures Series A investment led by Momenta, with participation from Rockwell Automation and Zürcher Kantonalbank.
- Investment aimed at accelerating deployment of DataHow’s digital bioprocess development platform, DataHowLab.
- DataHow pioneers hybrid models for bioprocess development, combining process knowledge with AI algorithms.
- DataHowLab offers user-friendly solution for richer bioprocess insights without extensive data-science knowledge.
- Platform accelerates process development, increases manufacturing productivity, and enables digital twin technology.
- Investment reflects belief in DataHow’s transformative potential in digital bioprocessing.
Main AI News:
In a significant move bolstering the advancement of AI-powered solutions for bioprocess development and manufacturing, DataHow, a Zurich-based leader in the field, has successfully concluded its Series A investment round. Spearheaded by Momenta, a prominent industrial impact venture capital firm, this round also saw participation from Rockwell Automation and Zürcher Kantonalbank. The infusion of capital is poised to expedite the proliferation of DataHow’s revolutionary digital bioprocess development and manufacturing platform, DataHowLab.
Founded in 2017 as an ETH spin-off by a cadre of seasoned researchers boasting industry expertise, DataHow has been at the forefront of pioneering hybrid models for bioprocess development. These models integrate hard-coded process knowledge with data-driven AI algorithms, empowering process engineers with deeper insights into complex manufacturing processes while minimizing data requirements.
With the innovative technologies housed within DataHowLab, the company stands ready to revolutionize bioprocess development and manufacturing:
- Enhanced Insights: DataHowLab offers a user-friendly digital solution equipped with advanced hybrid modeling technology, enabling process scientists to glean richer bioprocess insights sans the need for extensive data-science knowledge.
- Accelerated Development: By generating more profound process insights with reduced developmental effort and facilitating the transfer of insights across products and scales, DataHowLab expedites process development across all phases.
- Heightened Productivity: The platform supports the development of robust, high-yield processes, thereby bolstering manufacturing productivity through augmented process knowledge and AI-driven insights.
- Digital Twin Technology: Leveraging hybrid process models, DataHowLab enables process simulation and automated monitoring and control for both development and manufacturing phases.
This strategic investment underscores the conviction that DataHow’s technology is primed to revolutionize digital bioprocessing, playing a pivotal role in the ongoing digitalization thrust within the biopharmaceutical industry. The capital injection will facilitate the rapid advancement and market deployment of DataHowLab, while also forging formidable partnerships with Momenta and Rockwell Automation—entities renowned for their prowess in industrial automation and digital transformation.
Dr. Alessandro Butté, CEO and co-founder of DataHow, remarked, “We sought investment partners that comprehend the transformative potential of digitalization in manufacturing, possessing a deep-seated understanding of the market, ecosystem, technology, and culture. We are well-versed in research and development intricacies but require partners to propel our market expansion and solutions toward manufacturing and regulated production environments.”
Ken Forster, Executive Director of Momenta, echoed these sentiments, stating, “The past several years underscored the criticality of agile and rapid scaling in bioprocess manufacturing, facilitating the swift delivery of new medicines and compounds to enhance both the environment and quality of life. DataHow’s pioneering application of AI models stands to expedite the scale-up of bioprocess manufacturing.“
Arvind Rao, Vice President of Industry Solutions at Rockwell Automation, expressed enthusiasm for the collaboration, affirming, “We are thrilled to bolster DataHow’s journey from early-stage process development to commercial manufacturing. Through Rockwell’s engagement, DataHow can furnish customers with comprehensive solutions spanning the entire spectrum from laboratory to commercial scale manufacturing, thereby accelerating time to market, enhancing product yields, and curtailing costs.”
Conclusion:
DataHow’s successful Series A investment heralds a new era in AI-powered bioprocessing, with its innovative technologies poised to redefine process development and manufacturing in the biopharmaceutical industry. The infusion of capital underscores growing confidence in DataHow’s ability to drive digital transformation within the sector, signaling heightened competition and a shift towards AI-driven solutions in bioprocessing.
